Suzanne Hart - Balchem IR Contact Officer
| BCPC Stock | USD 143.12 0.68 0.47% |
Executive
Suzanne Hart is IR Contact Officer of Balchem since 2016.
| Tenure | 8 years |
| Address | 5 Paragon Drive, Montvale, NJ, United States, 07645 |
| Phone | 845 326 5600 |
| Web | https://www.balchem.com |
Balchem Management Efficiency
The company has return on total asset (ROA) of 0.0609 % which means that it generated a profit of $0.0609 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.109 %, meaning that it created $0.109 on every $100 dollars invested by stockholders. Balchem's management efficiency ratios could be used to measure how well Balchem manages its routine affairs as well as how well it operates its assets and liabilities. At present, Balchem's Return On Assets are projected to slightly decrease based on the last few years of reporting. The current year's Return On Equity is expected to grow to 0.17, whereas Return On Tangible Assets are forecasted to decline to 0.12. At present, Balchem's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 15.7 M, whereas Net Tangible Assets are forecasted to decline to about 129 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Shawn Severson | Gevo Inc | N/A | |
| Anne Tayac | Givaudan SA ADR | 55 | |
| Adrien Gonckel | Givaudan SA ADR | 63 | |
| Chris Thoen | Givaudan SA ADR | 57 | |
| Gregory Roda | Gevo Inc | 54 | |
| Corbin Barnes | Innospec | 51 | |
| Joe Fabbri | Givaudan SA ADR | 58 | |
| Antonio Silvestri | Perimeter Solutions SA | N/A | |
| Bradford Towne | Gevo Inc | 39 | |
| Trey Griffin | Innospec | 58 | |
| Heather Manuel | Gevo Inc | N/A | |
| Greg Roda | Gevo Inc | 54 | |
| Rafael Dregi | Perimeter Solutions SA | N/A | |
| Denis Baruffaldi | Perimeter Solutions SA | N/A | |
| Fabio Barone | Perimeter Solutions SA | N/A | |
| Noriko Yokozuka | Perimeter Solutions SA | 47 | |
| Simon HalleSmith | Givaudan SA ADR | 57 | |
| Marco Marzola | Perimeter Solutions SA | N/A | |
| Nancy Young | Gevo Inc | N/A | |
| Geoffrey Williams | Gevo Inc | 48 | |
| Gilles Andrier | Givaudan SA ADR | 62 | |
Management Performance
| Return On Equity | 0.11 | ||||
| Return On Asset | 0.0609 |
Balchem Leadership Team
Elected by the shareholders, the Balchem's board of directors comprises two types of representatives: Balchem inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Balchem. The board's role is to monitor Balchem's management team and ensure that shareholders' interests are well served. Balchem's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Balchem's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Frederic Boned, Senior Health | ||
| Brent Tignor, Senior Officer | ||
| Karin McCaffery, IR Contact | ||
| Hatsuki Miyata, General VP | ||
| Paul Coombs, Independent Director | ||
| William CPA, VP Officer | ||
| Edward McMillan, Independent Director | ||
| Mary Coelho, CFO, Chief Accounting Officer | ||
| Carl Bengtsson, CFO Treasurer | ||
| Job Gunsteren, Senior Products | ||
| Theodore Harris, CEO and President and Director | ||
| John Kuehner, Vice President - Operations, Executive Officer | ||
| David Fischer, Independent Director | ||
| Terry Coelho, CFO, Chief Accounting Officer | ||
| Mark Stach, General Counsel, Secretary | ||
| Jonathan Griffin, Senior Development | ||
| CPA CPA, Chief Officer | ||
| Francis Fitzpatrick, Vice President - Administration | ||
| John Televantos, Lead Independent Director | ||
| Scott Mason, Vice President of Manufacturing and Supply Chain | ||
| William Backus, CFO | ||
| Suzanne Hart, IR Contact Officer | ||
| Martin Bengtsson, CFO | ||
| Dino Rossi, Executive Chairman | ||
| Daniel Knutson, Director | ||
| Michael Sestrick, Senior CTO | ||
| David Ludwig, General Manager of ARC Specialty Products and VP | ||
| Matthew Wineinger, Director | ||
| Mary Brush, IR Contact Officer | ||
| Matthew Houston, General Counsel and Secretary | ||
| Perry Premdas, Independent Director | ||
| Martin Reid, Senior Officer |
Balchem Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Balchem a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.11 | ||||
| Return On Asset | 0.0609 | ||||
| Profit Margin | 0.12 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 4.96 B | ||||
| Shares Outstanding | 32.27 M | ||||
| Shares Owned By Insiders | 0.96 % | ||||
| Shares Owned By Institutions | 90.99 % | ||||
| Number Of Shares Shorted | 357.75 K | ||||
| Price To Earning | 42.37 X |
Pair Trading with Balchem
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Balchem position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Balchem will appreciate offsetting losses from the drop in the long position's value.Moving together with Balchem Stock
| 0.85 | DNMR | Danimer Scientific Financial Report 8th of May 2024 | PairCorr |
Moving against Balchem Stock
| 0.57 | CC | Chemours Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Balchem could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Balchem when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Balchem - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Balchem to buy it.
The correlation of Balchem is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Balchem moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Balchem moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Balchem can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Balchem. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Balchem Stock refer to our How to Trade Balchem Stock guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Complementary Tools for Balchem Stock analysis
When running Balchem's price analysis, check to measure Balchem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Balchem is operating at the current time. Most of Balchem's value examination focuses on studying past and present price action to predict the probability of Balchem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Balchem's price. Additionally, you may evaluate how the addition of Balchem to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |
Is Balchem's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Balchem. If investors know Balchem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Balchem listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.243 | Dividend Share 0.79 | Earnings Share 3.34 | Revenue Per Share 28.729 | Quarterly Revenue Growth (0.02) |
The market value of Balchem is measured differently than its book value, which is the value of Balchem that is recorded on the company's balance sheet. Investors also form their own opinion of Balchem's value that differs from its market value or its book value, called intrinsic value, which is Balchem's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Balchem's market value can be influenced by many factors that don't directly affect Balchem's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Balchem's value and its price as these two are different measures arrived at by different means. Investors typically determine if Balchem is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Balchem's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.